How to Get Vyleesi in Florida

What Is Vyleesi and Why Is It Prescribed?

Vyleesi (bremelanotide) is the only FDA-approved on-demand treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. It works by activating melanocortin receptors (MC1R and MC4R) in the central nervous system, which modulates desire pathways rather than peripheral blood flow. A single 1.75 mg subcutaneous dose is self-administered in the abdomen or thigh about 45 minutes before anticipated sexual activity, with no more than one dose per 24 hours and no more than approximately eight doses per month.

The FDA granted bremelanotide approval on June 21, 2019, based on two Phase 3 randomized controlled trials known collectively as RECONNECT. In those trials, women using bremelanotide reported statistically significant improvements in sexual desire and reductions in distress compared with placebo [1]. The most common adverse effect is nausea, reported in approximately 40% of participants, which is usually transient and peaks within about one hour of injection. Transient increases in blood pressure averaging 2 mmHg systolic have also been documented; for that reason, bremelanotide is contraindicated in women with pre-existing hypertension or cardiovascular disease [2].

HSDD affects an estimated 8 to 10% of adult women in the United States, making it one of the most common female sexual dysfunctions [3]. Florida's population of approximately 11.5 million adult women means hundreds of thousands may qualify for evaluation. Despite that prevalence, awareness of available FDA-approved therapies remains low among both patients and primary care clinicians [4].

Florida Telehealth Law and Bremelanotide Prescribing

Florida permits telehealth prescribing of bremelanotide under Florida Statute §456.47, which was substantially expanded in 2019. A clinician licensed in Florida may conduct a synchronous audio-video visit, establish a valid patient-clinician relationship, and issue a controlled or non-controlled prescription electronically without an in-person encounter.

Bremelanotide is not a controlled substance under the federal Controlled Substances Act or under Florida Statutes Chapter 893, so there are no DEA-schedule restrictions on telehealth prescribing. This makes the path to a telehealth Vyleesi prescription in Florida considerably simpler than for medications like buprenorphine or testosterone [5]. Clinicians must still conduct a thorough history, review relevant labs, screen for cardiovascular contraindications, and document a diagnosis of HSDD using validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R) and the Female Sexual Function Index (FSFI) [6].

Several national telehealth platforms now serve Florida patients specifically, including platforms focused on women's sexual health and hormone therapy. HealthRX connects Florida women with board-certified prescribers who can evaluate and, when appropriate, prescribe bremelanotide during a single 20- to 30-minute video visit.

Who Can Prescribe Vyleesi in Florida?

Any Florida-licensed prescriber with authority to write outpatient prescriptions may prescribe bremelanotide. That includes MDs and DOs with full prescriptive authority, Advanced Practice Registered Nurses (APRNs) operating under a protocol or with independent prescriptive authority, and Physician Assistants (PAs) prescribing under a supervising physician's delegated authority per Florida Statute §458.347 [7].

Specialists who commonly prescribe bremelanotide include gynecologists, sexual medicine physicians, and some psychiatrists with expertise in sexual dysfunction. Primary care physicians and family medicine practitioners in Florida are increasingly comfortable with HSDD evaluation following updated guidance from the International Society for the Study of Women's Sexual Health (ISSWSH) [8]. ISSWSH published a clinical practice guideline recommending that clinicians use the FSDS-R score as a primary distress measure and consider FDA-approved pharmacotherapy when psychosocial interventions alone are insufficient [8].

The table below outlines the HealthRX clinical decision framework for HSDD evaluation in Florida telehealth encounters:

HealthRX HSDD Telehealth Evaluation Framework (Florida)

| Step | Action | Tool or Threshold | |---|---|---| | 1 | Screen for sexual distress | FSDS-R total score ≥11 | | 2 | Confirm desire as the primary domain | FSFI desire subscale <3.3 | | 3 | Rule out hormonal contributors | TSH, free testosterone, estradiol, prolactin | | 4 | Cardiovascular screen | Resting BP <140/90 required; ECG if indicated | | 5 | Assess psychosocial factors | Brief PHQ-9, relationship history | | 6 | Confirm premenopausal status | Last menstrual period, FSH if ≥40 years old | | 7 | Document diagnosis and prescribe | E-prescribe to preferred Florida pharmacy |

Labs Required Before a Vyleesi Prescription in Florida

No single mandated lab panel exists in the FDA label for bremelanotide, but clinical guidelines and prescriber best practices in Florida typically require a set of baseline studies to rule out reversible causes of HSDD and contraindications to the medication [9].

A blood pressure reading is the most critical pre-prescribing data point. Women with baseline blood pressure at or above 140/90 mmHg should not receive bremelanotide due to the transient pressor effect documented in clinical trials, where mean maximum systolic BP increased by approximately 6 mmHg and mean maximum diastolic BP increased by approximately 4 mmHg within 12 hours of dosing [2]. Most Florida telehealth platforms ask patients to self-report a recent blood pressure reading or obtain one at a local pharmacy before the consult.

Beyond blood pressure, the ISSWSH guideline recommends evaluating thyroid-stimulating hormone (TSH) to exclude hypothyroidism as an HSDD driver, free testosterone and sex-hormone-binding globulin (SHBG) to screen for androgen insufficiency, prolactin to rule out hyperprolactinemia, and estradiol to confirm premenopausal status [8]. A complete metabolic panel is sometimes requested to screen for hepatic or renal conditions that might affect drug tolerance, though bremelanotide's primary metabolism via peptide hydrolysis means hepatic cytochrome P450 interactions are minimal [10].

Women already on oral hormonal contraceptives should be counseled that bremelanotide may reduce the absorption of co-administered oral drugs taken within 1 hour of injection, due to its transient gastric-motility-slowing effect [2]. Oral contraceptives should be taken at least 1 hour before or after the bremelanotide dose.

Lab results can usually be obtained through any Florida-licensed draw site, including Quest Diagnostics and LabCorp locations, which are widely available across the state. Several telehealth platforms can order labs directly to a local draw site as part of the intake process, eliminating the need for a separate primary care visit [11].

Getting a Vyleesi Prescription: Step-by-Step for Florida Patients

Step 1: Choose your prescriber type. Florida patients may see an in-person gynecologist or sexual medicine specialist, or they may use a Florida-licensed telehealth platform. Telehealth is permitted and does not require a prior in-person visit.

Step 2: Complete intake forms. Most platforms require the FSDS-R questionnaire (21 items scored 0-4, maximum 84; a score of 11 or above indicates clinically significant distress [6]) and the FSFI. Some also request a brief cardiovascular history.

Step 3: Attend the video visit. The prescriber will review your history, discuss HSDD diagnosis criteria per DSM-5 (persistent deficient desire causing marked distress, not explained by another condition or medication [12]), confirm the absence of cardiovascular contraindications, and answer questions about the injection technique and expected side effects.

Step 4: Receive the e-prescription. If prescribed, the clinician sends the prescription electronically to a pharmacy of your choice. Florida pharmacies can receive electronic prescriptions for bremelanotide under Florida's Electronic Prescribing for Controlled Substances (EPCS) infrastructure, though bremelanotide itself is non-controlled [13].

Step 5: Fill the prescription. You may use a retail pharmacy with brand-name Vyleesi, a mail-order pharmacy, or a Florida-licensed 503A compounding pharmacy for compounded bremelanotide (discussed below).

Step 6: Receive training. Most telehealth platforms provide an injection training video or live walk-through. The auto-injector is single-use and pre-filled; the injection site should be rotated between the abdomen and thigh.

The typical timeline from initial consult to medication in hand ranges from 3 business days (telehealth consult plus overnight mail-order pharmacy shipping) to 10 business days if prior authorization is attempted through commercial insurance.

Florida Pharmacies and 503A Compounding Access

Brand-name Vyleesi is distributed through specialty pharmacy networks. Palatin Technologies lists authorized specialty pharmacies on the Vyleesi website; patients can also request that a Florida-based specialty pharmacy source it through their wholesaler. The average wholesale price for one auto-injector kit (containing four 1.75 mg devices) is approximately $1,020 without insurance, though manufacturer assistance programs substantially reduce this cost for eligible patients [14].

Florida-licensed 503A compounding pharmacies may legally compound bremelanotide for individual patients when a licensed prescriber issues a patient-specific prescription. Under the federal Drug Quality and Security Act (DQSA) and Florida Board of Pharmacy rules (Florida Administrative Code 64B16-27), 503A pharmacies compound patient-specific preparations and ship within the state [15]. Compounded bremelanotide is typically available as a lyophilized powder for reconstitution or as a pre-filled subcutaneous syringe, at a cost ranging from $80 to $180 per vial, depending on concentration and pharmacy.

The Florida Board of Pharmacy conducts inspections of 503A facilities and requires compliance with USP standards, including USP Chapter 797 for sterile preparations [16]. Patients selecting a compounding pharmacy should verify current licensure through the Florida Department of Health's online licensure verification portal and confirm the pharmacy holds active sterile compounding authority.

503B outsourcing facilities, which compound without patient-specific prescriptions for office use, are federally regulated by the FDA rather than state pharmacy boards [15]. Bremelanotide is not currently on the FDA's 503B Bulks List, so 503B outsourcing facilities cannot legally compound it for office stock [17].

Insurance Coverage and Cost in Florida

Florida Medicaid does not cover Vyleesi for HSDD. The Florida Medicaid preferred drug list currently restricts bremelanotide coverage and does not include it in any covered formulary tier for this indication.

Coverage through commercial insurance plans varies. Some Florida Blue, Aetna, and Cigna formularies include bremelanotide at a specialty tier, which often means a copay between $50 and $200 per fill after the deductible, though prior authorization is almost universally required [18]. Prior authorization for bremelanotide in Florida typically demands documentation of an FSDS-R score at or above 11, confirmation that the condition is not attributable to another medical condition or current medication, and evidence that at least one psychosocial or behavioral intervention was considered or attempted [19].

The Palatin Technologies patient assistance program (operated through RxHope) may reduce out-of-pocket cost to $0 per month for commercially insured patients who meet income criteria. Uninsured patients with household incomes below 400% of the federal poverty level may qualify for the full patient assistance program, which provides brand-name Vyleesi at no cost. Patients should call RxHope at 1-877-RxHOPE-1 or visit the manufacturer's patient support site to check eligibility before assuming they must pay retail price.

Compounded bremelanotide from a Florida 503A pharmacy carries no insurance reimbursement pathway but avoids the prior authorization process entirely. For patients whose commercial insurance requires prior authorization cycles lasting two to three weeks, the compounded route may actually deliver the medication faster at a lower net cost.

Clinical Evidence Supporting Bremelanotide

The RECONNECT program comprised two identically designed, double-blind, placebo-controlled Phase 3 trials enrolling a combined 1,247 premenopausal women with HSDD across 89 clinical sites. Published in Obstetrics and Gynecology in 2019, the trials demonstrated that bremelanotide produced a statistically significant increase in the number of satisfying sexual events (SSEs) per month compared with placebo (P<0.001 for the combined primary endpoint analysis) [1]. Women in the bremelanotide arms also reported a significant reduction in FSDS-R desire distress scores relative to placebo at week 8 and week 24 [1].

Nausea was the most common adverse event, occurring in 40.0% of bremelanotide users vs. 1.2% of placebo users, but led to discontinuation in only 8.0% of the bremelanotide group [1]. The investigators concluded that bremelanotide's benefit-risk profile supports its use as an on-demand therapy, particularly for women who prefer not to take a daily medication (flibanserin, the only other FDA-approved HSDD drug, requires daily dosing) [20].

A 52-week open-label extension study confirmed that the cardiovascular signal remained small and non-progressive with repeated use. Mean systolic BP elevation of approximately 2 mmHg from baseline was observed, which normalized within 12 hours of each dose [2]. No serious cardiovascular events were attributed to bremelanotide in either the Phase 3 program or the extension study.

A 2021 review in the Journal of Sexual Medicine noted that real-world tolerability appeared consistent with trial data, and that patient-reported outcomes at 3 months of use showed sustained improvements in desire and distress scores [21]. The American College of Obstetricians and Gynecologists (ACOG) acknowledges bremelanotide as an FDA-approved option for HSDD in its guidance on female sexual dysfunction, while emphasizing that patient selection and cardiovascular screening are essential before prescribing [22].

The ISSWSH Process of Care for the Identification of Sexual Concerns and Problems in Women, published in the Journal of Sexual Medicine, provides a stepwise algorithm that places pharmacotherapy alongside psychotherapy and hormone optimization as second-line options when initial counseling is insufficient [8]. Specifically, the guideline states: "For women with HSDD who have not responded to psychosocial interventions or for whom such interventions are not accessible, FDA-approved pharmacotherapy with flibanserin or bremelanotide should be discussed" [8].

Transferring an Existing Vyleesi Prescription to Florida

Women relocating to Florida or establishing a secondary residence in the state can transfer an existing bremelanotide prescription under standard pharmacy transfer rules. Because bremelanotide is non-controlled, Florida law (Florida Statute §465.0276) allows a pharmacist to transfer the remaining authorized refills from an out-of-state pharmacy to any Florida-licensed pharmacy [23]. The receiving pharmacy contacts the original pharmacy directly; the patient typically needs only to provide the original pharmacy's name and phone number.

The prescriber relationship is separate from the prescription transfer. If the original prescriber is not licensed in Florida, they cannot issue new prescriptions or refill authorizations for Florida patients. Patients whose prescriber is out-of-state should establish care with a Florida-licensed clinician for ongoing management. A single telehealth visit with a Florida-licensed provider, reviewing prior records and confirming the HSDD diagnosis, is generally sufficient to continue care without repeating the full initial evaluation.

Managing Side Effects After Starting Vyleesi

Nausea is the most frequently reported side effect and the most common reason for discontinuation. The FDA label for bremelanotide recommends that women who experience significant nausea take an over-the-counter antiemetic such as ondansetron 4 mg or promethazine 12.5 mg approximately 30 minutes before injection [2]. Florida prescribers commonly co-prescribe ondansetron for the first two to four doses while the patient assesses her individual tolerability.

Flushing and headache each occur in approximately 20% of users in clinical trials [1]. These effects are also transient, peaking within 1 to 2 hours post-injection and resolving within 12 hours for most patients. Women should avoid driving or operating machinery within 2 hours of the injection if they experience these effects.

Hyperpigmentation of the face, gums, or breasts has been reported with repeated use. This occurs due to bremelanotide's agonism at MC1R, the same receptor targeted by melanocyte-stimulating hormone. In the 52-week open-label extension study, focal hyperpigmentation was reported in approximately 1% of participants and was generally reversible after discontinuation [2]. Patients with darker baseline skin tones should be counseled about this possibility before starting therapy [24].